SJ

Sunil Jagdishlal Brahamkhatri

Director Director DIN 08082193
DIN 08082193 First appointment Mar 2018 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Past companies 2 historical roles
Total affiliations 2 Since Mar 2018
Shareholding value •••• Premium profile

About Sunil Jagdishlal Brahamkhatri

Data last updated:

Sunil Jagdishlal Brahamkhatri was a Director at Trovip Pharmaceuticals Private Limited (2018–2020) and Director at Craton Pharmaceuticals Private Limited (2018–2021). The companies operate in Pharma.

DIN 08082193
Primary Designation Director
Industry Pharma
First Appointment 09 Mar 2018

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director09 Mar 20182018Active
Director28 Nov 20182018₹12.4 Lakh (FY 2021)Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Trovip Pharmaceuticals Private Limited
Craton Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Sunil Jagdishlal Brahamkhatri

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Sunil Jagdishlal Brahamkhatri

Sunil Jagdishlal Brahamkhatri was first appointed on 09 Mar 2018 as Director at Trovip Pharmaceuticals Private Limited.

Sunil Jagdishlal Brahamkhatri held 2 earlier board appointments: Trovip Pharmaceuticals Private Limited (Director, 09 Mar 2018 to 16 Jun 2020); Craton Pharmaceuticals Private Limited (Director, 28 Nov 2018 to 14 Dec 2021).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available